Similar Search Results

Cost-of-illness studies in nine Central and Eastern European countries

Brodszky, Valentin; Beretzky, Zsuzsanna; Baji, Petra; … - In: The European journal of health economics : HEPAC ; … 20 (2019), pp. S155-S172

Persistent link: https://www.econbiz.de/10012060954

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

Gulácsi, László; Rencz, Fanni; Péntek, Márta; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 27-34

While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10010993927

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 65-71

The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European...

Persistent link: https://www.econbiz.de/10010993971

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

Gulácsi, László; Rencz, Fanni; Péntek, Márta; … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 27-34

Persistent link: https://www.econbiz.de/10010376453

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 65-71

Persistent link: https://www.econbiz.de/10010377073